Engineered nanomedicines block the PD-1/PD-L1 axis for potentiated cancer immunotherapy
文献类型：期刊论文
| 作者 | Li, Jun-hao3,4,5; Huang, Lu-jia2,3,4; Zhou, Hui-ling3,4; Shan, Yi-ming2,3,4; Chen, Fang-min2,3,4; Lehto, Vesa-Pekka1; Xu, Wu-jun1; Luo, Li-qiang5; Yu, Hai-jun2,3,4
|
| 刊名 | ACTA PHARMACOLOGICA SINICA
 |
| 出版日期 | 2022-04-28 |
| 页码 | 10 |
| 关键词 | cancer immunotherapy immune checkpoint blockade PD-1/PD-L1 axis nanomedicine nanosized drug delivery systems |
| ISSN号 | 1671-4083 |
| DOI | 10.1038/s41401-022-00910-w |
| 通讯作者 | Huang, Lu-jia(huanglujia@simm.ac.cn) ; Xu, Wu-jun(wujun.xu@uef.fi) ; Yu, Hai-jun(hjyu@simm.ac.cn) |
| 英文摘要 | Immunotherapy, in particular immune checkpoint blockade (ICB) therapy targeting the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) axis, has remarkably revolutionized cancer treatment in the clinic. Anti-PD-1/PD-L1 therapy is designed to restore the antitumor response of cytotoxic T cells (CTLs) by blocking the interaction between PD-L1 on tumour cells and PD-1 on CTLs. Nevertheless, current anti-PD-1/PD-L1 therapy suffers from poor therapeutic outcomes in a large variety of solid tumours due to insufficient tumour specificity, severe cytotoxic effects, and the occurrence of immune resistance. In recent years, nanosized drug delivery systems (NDDSs), endowed with highly efficient tumour targeting and versatility for combination therapy, have paved a new avenue for cancer immunotherapy. In this review article, we summarized the recent advances in NDDSs for anti-PD-1/PD-L1 therapy. We then discussed the challenges and further provided perspectives to promote the clinical application of NDDS-based anti-PD-1/PD-L1 therapy. |
| WOS关键词 | IMMUNE CHECKPOINT BLOCKADE ; ANTITUMOR IMMUNITY ; PD-1 BLOCKADE ; NIVOLUMAB ; IPILIMUMAB ; RESISTANCE ; ANTI-PD-1 ; PEMBROLIZUMAB ; METASTASIS ; ANTIBODIES |
| 资助项目 | National Natural Science Foundation of China[51873228] ; National Natural Science Foundation of China[32050410287] ; International Cooperation Project of Science and Technology Commission of Shanghai Municipality[20430711800] |
| WOS研究方向 | Chemistry ; Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000788463900001 |
| 出版者 | NATURE PUBL GROUP |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/300983]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Huang, Lu-jia; Xu, Wu-jun; Yu, Hai-jun |
| 作者单位 | 1.Univ Eastern Finland, Dept Appl Phys, Kuopio 70211, Finland 2.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Mat Med, Ctr Pharmaceut, Shanghai 201203, Peoples R China 4.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China 5.Shanghai Univ, Coll Sci, Shanghai 200444, Peoples R China |
| 推荐引用方式 GB/T 7714 | Li, Jun-hao,Huang, Lu-jia,Zhou, Hui-ling,et al. Engineered nanomedicines block the PD-1/PD-L1 axis for potentiated cancer immunotherapy[J]. ACTA PHARMACOLOGICA SINICA,2022:10. |
| APA | Li, Jun-hao.,Huang, Lu-jia.,Zhou, Hui-ling.,Shan, Yi-ming.,Chen, Fang-min.,...&Yu, Hai-jun.(2022).Engineered nanomedicines block the PD-1/PD-L1 axis for potentiated cancer immunotherapy.ACTA PHARMACOLOGICA SINICA,10. |
| MLA | Li, Jun-hao,et al."Engineered nanomedicines block the PD-1/PD-L1 axis for potentiated cancer immunotherapy".ACTA PHARMACOLOGICA SINICA (2022):10. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。